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Abstract
Background: To assess gliomas using image-based estimation of cellularity, we utilized isotropic diffusion spectrum
imaging (IDSI) on clinically feasible diffusion tensor imaging (DTI) and compared it with amino acid uptake
measured by α[11C]methyl-L-tryptophan positron emission tomography (AMT-PET).
Methods: In 10 patients with a newly-diagnosed glioma, metabolically active tumor regions were defined in both
FLAIR hyperintense areas and based on increased uptake on AMT-PET. A recently developed independent
component analysis with a ball and stick model was extended to perform IDSI in clinical DTI data. In tumor regions,
IDSI was used to define tumor cellularity which was compared between low and high grade glioma and correlated
with the glioma proliferative index.
Results: The IDSI-derived cellularity values were elevated in both FLAIR and AMT-PET-derived regions of high-grade
gliomas. ROC curve analysis found that the IDSI-derived cellularity can provide good differentiation of low-grade
from high-grade gliomas (accuracy/sensitivity/specificity of 0.80/0.80/0.80). . Both apparent diffusion coefficient
(ADC) and IDSI-derived cellularity showed a significant correlation with the glioma proliferative index (based on
Ki-67 labeling; R = 0.95, p < 0.001), which was particularly strong when the tumor regions were confined to areas
with high tryptophan uptake excluding areas with peritumoral edema.
Conclusion: IDSI-MRI combined with AMT-PET may provide a multi-modal imaging tool to enhance pretreatment
assessment of human gliomas by evaluating tumor cellularity and differentiate low-grade form high-grade gliomas.
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Background
Malignant gliomas, including WHO grade IV glioblast-
omas, are among the most lethal malignancies in the
human brain [1, 2]. The ability to distinguish actively
proliferating neoplastic cells from non-tumoral lesions is
critical to the clinical management of glioma patients.
Current clinical neuroimaging techniques, including
T1-weighted images with gadolinium (GAD) and fluid-
attenuated inversion recovery (FLAIR), do not accur-
ately differentiate regions with proliferating tumor cells
from vasogenic edema and necrosis, and they are also
inaccurate in predicting glioma grade and proliferative
activity [3]. Thus, precise surgical planning for tailored
tumor resection is limited based on current conven-
tional MRI techniques. Advanced imaging techniques,
including perfusion and diffusion MRI as well as posi-
tron emission tomography (PET) are being actively in-
vestigated to overcome some of the limitations of
conventional MRI modalities [3].
Infiltrating gliomas often show high amino acid uptake
extending beyond the contrast-enhancing tumor mass
indicating glioma cell-infiltrated brain tissue [4, 5]. In
clinical studies, several different amino acid PET radio-
tracers, including [11C]methionine, 18F-fluoroethyl-tyro-
sine (FET), 18F-fluoro-Ldihydroxy-phenylalanine (FDOP
A), and α[11C]methyl-L-tryptophan (AMT) have been
tested for glioma imaging, and each of them has their
unique advantages and limitations [6]. Our center has
recently tested the clinical use of AMT-PET for glioma
* Correspondence: jeongwon@pet.wayne.edu
1Departments of Pediatrics and Neurology, Wayne State University School of
Medicine, 3901 Beaubien St., Detroit, MI 48201, USA
2PET Center and Translational Imaging Laboratory, Children’s Hospital of
Michigan, Detroit, MI, USA
Full list of author information is available at the end of the article
© 2015 Jeong et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Jeong et al. Cancer Imaging  (2015) 15:10 
DOI 10.1186/s40644-015-0045-1
imaging [6–11]. AMT is transported to tumor tissue
via the large neutral amino acid transporter and can be
metabolized via the immunomodulatory kynurenine
pathway [6, 8, 12], whose activation leads to tumoral
immune tolerance [13]. In clinical studies, increased
AMT uptake was found to be useful to: (i) detect both
low- and high-grade gliomas and identify glioma-
infiltrated brain in non-enhancing brain regions (veri-
fied by histology) [5–7]; (ii) accurately differentiate
recurrent gliomas from radiation injury [9]; and (iii)
predict post-treatment survival in malignant gliomas
[11]. However, PET has limitations, including relatively
low spatial resolution and also limited clinical availabil-
ity and high cost as compared to MRI techniques.
Recently, restricted diffusion measured by the apparent
diffusion coefficient (ADC) on diffusion weighted imaging
(DWI) was compared to postmortem cell density obtained
by ex vivo histology of high-grade gliomas [14]. This com-
parison showed significantly increased cell density in
the regions of low ADC (<0.929 × 10−3 mm2/s) and co-
localized with FLAIR hyperintensity. However, DWI-
derived ADC measures the average diffusion of water
molecules within each voxel, limiting the differentiation
of active tumor from necrosis [14]. Recent comparative
studies of DWI-ADC and FDOPA, MET and FET PET
showed that areas with restricted diffusion (low ADC)
did not correlate with foci of high amino acid metabol-
ism in human gliomas [15–17]. This discrepancy indi-
cated that restricted diffusion may be affected not only
by tumor cell density and metabolic activity but also
other factors, such as ischemia or compression.
In order to detect subtle changes within voxels due to
axonal injury, dense cellularity, demyelination, and
edematous fluid in a mouse model of multiple sclerosis,
diffusion basis spectrum imaging (DBSI) was developed.
This technique can resolve multiple anisotropic and a
spectrum of isotropic diffusion tensors in high angular
resolution diffusion imaging (HARDI), by sampling
water diffusion at 99 encoding directions and multiple
diffusion weighting b-values [18]. It was reported that
axonal water diffusion is distributed in non-Gaussian
and the resulting signal decay is non-monoexponential
requiring at least three b-values [19]. However, due to
the long scanning time required for multi-b value
HARDI acquisition, translation of this method to clinical
practice is difficult, especially in patients with brain tu-
mors routinely requiring several MRI scans for pre-
treatment diagnosis and post-treatment monitoring.
The present study investigates whether the DBSI
technique can be implemented for clinically feasible
diffusion tensor imaging (DTI) studies which have been
widely used for axonal tractography analysis to guide
presurgical planning of tumor resection. It is heuristic-
ally presumed that independent component analysis
with ball and stick model (ICA + BSM) [20] may pro-
vide accurate initial parameters of isotropic diffusion
spectrum imaging (IDSI) [18] to assess tumor cellular-
ity in clinical DTI data. The aim of the present study
was to evaluate IDSI with ICA + BSM for clinical DTI
data, specifically, to detect the degree of tumor cellular-
ity in human gliomas. We hypothesized that malignant
gliomas would show increased cellularity (i.e., high
fraction of isotropic compartment at a low band of the
diffusivity spectrum), as a result of increased restricted
isotropic diffusivity within the active tumor region. We
used both AMT PET and histopathology to evaluate
the metabolic and cell proliferation marker correlates
of increased cellularity defined by this novel approach.
Methods
Subjects and data acquisition
The study included ten patients with histopathologically-
verified WHO grade II (n = 5) and grade IV (n = 5) gli-
omas (Table 1). The study was approved by Wayne State
University’s Institutional Review Board and written in-
formed consent was obtained from all participants.
All MRI scans were performed on a 3T Philips scanner
equipped with an eight-channel head coil. For IDSI, DTI
data were gathered at repetition time (TR) = 10,870 ms,
echo time (TE) = 108.9 ms, field of view (FOV) = 224 cm,
128 × 128 acquisition matrix, 2 mm thickness using 15
isotropic gradient directions with b-value = 1000 s/mm2,
one b = 0 acquisition, and number of excitations = 1. For
ADC, DWI data were acquired at 2 b-values of 0 and
1000 s/mm2 with all other imaging parameters the same as
described above for IDSI. As a part of the clinical MRI
protocol, conventional imaging sequences were acquired
including axial pre- and post-contrast T1-weighted as well
as T2-weighted and fluid attenuation inversion recovery
(FLAIR) images.
AMT-PET images were acquired using a Siemens
EXACT/HR whole-body positron emission tomograph
(Siemens Medical Systems, Knoxville, TN), as described
previously [5, 7, 9]. At 25 min after tracer injection, a
dynamic emission scan of the brain (7 × 5 min) was
started. Measured attenuation correction, scatter, and
decay correction were applied. All images were recon-
structed with filtered backprojection using a Hanning fil-
ter, yielding images with an in-plane resolution of 7.5 ±
0.4 mm at full-width half-maximum, and 7.0 ± 0.5 mm
full-width half-maximum in the axial direction. For the
present study, image analysis was performed using AMT
standardized uptake value (SUV) images. The SUV was
calculated by dividing the average tracer concentration in
tissue at 30–55 min by the ratio of injected activity and
patient weight. Regions with increased AMT SUV in the
lobes encompassing the tumor were defined as areas
showing at least 36 % higher AMT SUV as compared to
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mean AMT SUV in contralateral normal cortex. This
threshold was established in our previous study [5]
where this cutoff value provided an optimal pretreat-
ment differentiation between the metabolically active
tumor volume and peritumoral edema. In the same
study, histopathology of stereotactically-resected brain
tissue samples also verified that AMT-positive regions
outside the contrast-enhancing tumor mass detected
glioma-infiltrated brain when using this cutoff thresh-
old [5].
Standard neuropathological examination of tumor
specimens was performed by an experienced board-
certified neuropathologist (W.J.K.). Immunohistochemi-
cal staining for Ki-67 (monoclonal antibody, Dako, Santa
Barbara, CA) was performed to assess glioma proliferative
activity. The Ki-67 labeling index was determined by iden-
tifying the areas of greatest tumor cellularity, examining at
least 10 high-power fields (40×) on an Olympus micro-
scope, and determining the ratio between the number of
Ki-67-positive tumor cell nuclei and the total number of
tumor cell nuclei in each high-power field (Fig. 1). The
proliferation index was expressed as a percent range (low-
est to highest, e.g., 5-10 %). Small, isolated fields with
higher Ki-67 labeling that were not reflective of the entire
tumor mass were excluded from the analysis.
Assessment of tumor cellularity from clinical DTI data
The present study utilized an ICA + BSM analysis [20]
to facilitate the numerical procedure of model selection
and non-linear optimization in a conventional IDSI
framework [18] (e.g., details are available in Additional
file 1). In brief, using IDSI fitting analysis constrained
by ICA + BSM, voxel-wise isotropic diffusion fractions,
fdk=1,2,3,4 were estimated at four discrete isotropic spectral
bands, d1 = 0, d2 = 1.0, d3 = 2.0 and d4 = 3.0 × 10
−3 mm2/s.
To assess levels of the cellularity, we defined IDSI-
cellularity value at every voxel by summing two low spectral
fractions (i.e., cellularity = fd1 + fd2). The upper bound of the
fraction (dk = 1.0 × 10
−3 mm2/s) was selected according to
maximal ADC threshold (0.929 × 10−3 mm2/s) measured
for the cutoff value for hypercellularity previously validated
by histology [14].
For the voxel-wise comparison of individual patients,
T1-GAD, FLAIR, DWI-ADC and AMT-SUV, images
were co-registered to the b0 image applying the corre-
sponding affine transformation that optimizes the cost
function of normalized mutual information embedded in
SPM 8 software (http://www.fil.ion.ucl.ac.uk/spm/).
Performance assessment of IDSI-derived cellularity to dif-
ferentiate high-grade from low-grade gliomas
Receiver operating characteristic (ROC) curve analysis
was utilized to assess the accuracy of the DWI-ADC
and the IDSI-derived cellularity to differentiate high-
grade (grade IV, n = 5) from low-grade gliomas (grade
II, n = 5) in two, differently defined tumoral regions of
interest (ROI), 1) FLAIR ROI, which manually delin-
eated to include hyperintense regions in the area of the
presumed tumor on FLAIR images by including all
tumor regions showing higher intensity than normal
contralateral cortex, and 2) AMT-SUV ROI including
voxels with high AMT-SUV above the 36 % threshold
as compared to contralateral normal cortex, Y = tumor/
cortex ration of AMT-SUV ≥ 1.36 [5]. In each of the
two tumoral ROIs, IDSI-derived cellularity was mea-
sured to quantify the degree of cellularity in individual
patients. The ROC curves were fitted using non-linear
square fit of the measured true positive ratio (sensitiv-
ity) to the measured false positive rate (1-specificity).
The area under curve (AUC) was then calculated from
the fitted curve for the comparison.
Table 1 Patient demographics and tumor characteristics
Pt. Age(years) Gender Tumor location Glioma grade Tumor proliferative index (%) MRI max. tumor volume
(10−3mm3)
Tumor/cortex ratio of AMT-SUV
1 70 F Lt P IV 50 % 53.8 1.7
2 54 F Rt P IV 25-30 % 103.3 1.9
3 37 F Lt F II 5-7 % 13.5 1.6
4 34 F Rt P II 2-3 % 1.5 1.8
5 70 F Rt T-P IV 20-25 % 24.6 2.0
6 78 M Lt T IV 30 % 50.7 2.2
7 45 M Rt T II 5 % 3.6 1.9
8 47 M Lt T IV 10-15 %a 42.7 1.6
9 18 M Rt F II 1-2 % 4.0 1.1
10 30 M Lt T-F II 5 % 2.4 2.4
Pt. patient, F female, M male, Lt left, Rt right, F frontal, T temporal, P parietal, AMT= α[11C]methyl-L-tryptophan, SUV standardized uptake value
aThis glioma had evidence of intratumoral hemorrhage and widespread necrosis on histopathology
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Correlation of glioma proliferative index with DWI-ADC
and IDSI-derived cellularity
In order to assess IDSI-derived cellularity to predict
tumor proliferative activity, we correlated mean glioma
Ki-67 labeling index with the mean values of DWI-ADC
and IDSI-derived cellularity obtained in both FLAIR and
AMT-SUV derived tumor ROIs using Pearson’s correla-
tions. For this analysis, median Ki-67 labeling index from
nine patients were used. One patient with a grade IV gli-
oma (Pt. 8) had evidence of intratumoral hemorrhage
before surgery. Histopathology showed densely cellular
tumor parts but an unusually low Ki-67 index for a grade
IV tumor, due to extensive necrotic and hemorrhagic tis-
sue damage. Therefore, in this case, Ki-67 labeling index
was not an appropriate surrogate marker of tumor cellu-
larity and was excluded from this analysis.
Results
Representative examples of AMT-SUV, T1-GAD, ADC,
and IDSI-derived cellularity Σdk¼0:0010dk¼0 fdk
 
are shown
for two patients with a grade IV glioma and two patients
with a grade II glioma (Fig. 1). As marked by white ar-
rows, the IDSI-derived cellularity detected a cluster of
voxels in the region showing increased AMT-SUV and
decreased ADC values in both grade IV gliomas. In con-
trast, no voxels with increased cellularity was found in
either grade II gliomas, which showed lower cellularity
Fig. 1 Representative images of AMT-SUV, T1-GAD, DWI-ADC and IDSI-cellularity obtained from two patients with a grade IV glioma (a and b),
and two patients with a grade II glioma (c and d). The tumor in Pt. 1 (a) showed contrast enhancement surrounding a necrotic core on MRI.
AMT-PET showed high uptake (in red) in the tumor region that surrounded the necrotic core with no AMT uptake; on histopathology, this tumor
had dense cellularity and high Ki-67 labeling index in the region showing high AMT uptake (up to 50 % of the nuclei, as illustrated by the
immunostaining on the bottom left). The tumor of Pt. 2 (b) showed minimal contrast enhancement on MRI, moderate cellularity and lower Ki-67
labeling index (25-30 % of the nuclei). Increased AMT-SUV showed the extent of the tumor with no necrotic core. White arrows indicate the
cluster of voxels showing increased cellularity corresponding to increased AMT-SUV and decreased ADC value. Note that none of the voxels show
high cellularity in the region of increased AMT-SUV in patients with a low-grade glioma (Pt. 3 and 4), consistent with low proliferative index and
lower cellularity on histopathology, despite moderately high AMT uptake in these tumors
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and low Ki-67 labeling indices (up to 7 %) on histopath-
ology. This suggests that the proposed IDSI-derived cel-
lularity measure may provide an effective tool to identify
tumors with high proliferative activity.
Figure 2 shows scatter plots of IDSI-derived cellularity
obtained from FLAIR ROIs of five patients with grade
IV gliomas and five patients with grade II gliomas. The
color of each dot indicates the value of IDSI-derived cel-
lularity for each voxel of the tumor region. Increased
IDSI-derived cellularity was apparent in the voxels with
higher AMT-SUV and lower ADC in high-grade glioma
patients. Similarly, Fig. 3 represents scatter plots of
IDSI-derived cellularity obtained from AMT-SUV ROIs
of five patients with grade IV gliomas and four patients
with grade II gliomas (in one grade II tumor, AMT-SUV
increase did not exceed the 36 % cutoff threshold (i.e.,
Y ≥ 1.36), and this tumor was not included in this ana-
lysis). Compared with plots obtained in FLAIR-based
ROIs (Fig. 2), increased IDSI-derived cellularity was more
apparent in the voxels with higher AMT-SUV and lower
ADC only in high-grade glioma patients, while low-grade
gliomas showed no voxels with high cellularity.
In differentiating high-grade to low-grade gliomas,
compared with the DWI-ADC, the IDSI-derived cellu-
larity showed a slightly higher probability to differentiate
high grade from low grade glioma, resulting in ‘good
test’ for both FLAIR and AMT-SUV tumoral ROIs
(Fig. 4, AUC = 0.83 and 0.88 for FLAIR and AMT-SUV).
Delineation of the tumor area with high cellularity was
performed by thresholding the IDSI-derived cellularity
map at its optimal cut-off value (0.17) in both FLAIR
and AMT-SUV tumoral ROIs, yielding the accuracy/sensi-
tivity/specificity of 0.80/0.80/0.80 to differentiate the voxels
of grade IV from those of grade II in the ROC analysis
(Fig. 5). For the comparison with DWI-derived ADC
cellularity, previously histology-validated maximal ADC
thresholds, 0.93 × 10−3 mm2/s [14] and 1.22 × 10−3 mm2/s
[21] were applied to define the active tumor areas inside
hyper intense FLAIR regions of the same patients. The
IDSI-derived cellularity detected larger proliferating tumor
areas with high cellularity than the DWI-derived ADC
cellularity. On the other hand, the high-cellularity areas
were smaller than the areas showing high AMT SUV in
all patients with grade IV glioma.
IDSI-derived cellularity correlated positively with Ki-67
labeling index when tested using the FLAIR-based tumor
ROIs(R = 0.77, p = 0.015, Fig. 6a). The correlation was
even stronger when using the AMT-PET-based tumor
ROIs (R = 0.95, p < 0.001, Fig. 6b). This is not surprising,
because the AMT-SUV ROIs include the active tumor re-
gions, while T1-FLAIR ROI can include vasogenic edema.
Because Ki-67 values are derived from tumor tissue but
not from tissue with edema, the correlation is stronger
with the PET-based regions.
Discussion
The present study demonstrates the potential clinical
use of IDSI-derived cellularity as a new measure for
clinically feasible DTI studies to assess hypercellularity
in malignant gliomas. In grade IV gliomas, high IDSI-
derived cellularity values were found in portions of
both areas showing increased FLAIR signal intensity,
which can include both tumor and peritumoral edema,
and in regions with increased AMT-SUV, a PET im-
aging marker of glioma mass and glioma-infiltrated
peritumoral brain parenchyma [5, 7]. In these regions,
the cellularity parameter had a high accuracy to differ-
entiate grade IV from grade II gliomas. By adapting the
isotropic diffusion spectrum to measure restricted iso-
tropic diffusivity in the framework of ICA + BSM, our
data also suggest that this technique can provide a
Fig. 2 Scatter plots of the IDSI-derived cellularity compared with Y(tumor/cortex ratio of AMT-SUV) and DWI-ADC values obtained from
FLAIR-derived tumor regions of five patients with grade IV gliomas (a), and five patients with grade II gliomas (b). Each plot shows the
summation of individual voxels for which DWI-ADC and Y(AMT-SUV ratio) are plotted on the x- and y-axes, respectively, while cellularity
values are indicated by color. Note that increased cellularity tends to occur in voxels with low ADC values for all grade IV glioma cases,
while there were much fewer voxels with increased cellularity in the grade II gliomas
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Fig. 3 Scatter plots of the IDSI-derived cellularity compared with Y(tumor/cortex ratio of AMT-SUV) and DWI-ADC values obtained from AMT-PET-derived
tumor regions of five patients with grade IV gliomas (a), four patients with grade II gliomas (b). Pt. 10 excluded from grade IV glioma since no tumor/cortex
ratio was found above the threshold of 1.36 (Y≥ 1.36). Each plot represents an individual voxel for which DWI-ADC and Y(AMT-SUV ratio) are plotted on
the x- and y-axes, while cellularity values are indicated by color. Note that increased cellularity tends to occur in voxels with low ADC values for all grade IV
glioma cases, and also that there were no voxels with increased cellularity in the grade II gliomas
Fig. 4 ROC curves (blue: measured, red: fitted) obtained from FLAIR-based tumor regions (a) and high AMT-SUV tumor regions (b) in order to
differentiate grade IV gliomas from grade II gliomas using DWI-ADC and IDSI-cellularity. In each curve, true positive rate (y-axis) was estimated
using non-linear least square fit of the false positive rate (x-axis) using the equation of y = 1 − 1/(1 + (x/a)b)c where a, b and c are the model
coefficients. For the comparison, the area under curve (AUC) was finally calculated from the fitted curve
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novel imaging marker to estimate glioma proliferative
activity while using a clinically feasible DTI acquisition.
In the literature, there is disagreement regarding the
interpretation of DWI-derived ADC changes in brain tu-
mors. Several studies [22–26] reported an increased
tumor cellularity in the region showing decreased ADC
values, while other studies [27, 28] showed necrosis in
the regions of low ADC. Also, DWI-derived ADC is sen-
sitive to other tissue characteristics, including the pres-
ence of extracellular fluid due to vasogenic edema or
tumor-induced destruction of the extracellular structure.
In addition, gliomas often contain a variable number of
infiltrating immune cells and microglia [29, 30], which
can be numerous in high-grade gliomas and may affect
the measured diffusion characteristics. Therefore, it is
unclear how useful restricted diffusion could be to
indicate “hypercellularity” to identify tumor-infiltrated
brain and localize such regions outside of the contrast-
enhancing tumor mass.
In the present study, AMT-PET was combined with
DTI images to determine whether IDSI-MRI could be
used to detect active tumor regions while excluding
areas with necrosis and vasogenic edema, which show
very low AMT uptake [5]. The results show that such
detection can be done with great accuracy in high-
grade gliomas, which always show a marked increase of
AMT-SUV [7]. In these regions, the IDSI approach de-
tected increased cellularity consistent with the tumors’
strong proliferative activity and dense cellularity, as
demonstrated on histopathology (Fig. 1). In contrast, all
low-grade gliomas showed relatively low cellularity
values by IDSI, despite the variable increase of AMT
Fig. 5 Receiver operating characteristic (ROC) curve analysis was applied to estimate the optimal cut-off value of IDSI-cellularity (0.17), yielding
the accuracy/sensitivity/specificity of 0.80/0.80/0.80 to differentiate grade IV gliomas from grade II gliomas. The detection of the proliferating
tumor cells was performed by thresholding of IDSI-derived cellularity at its cut-off value. Red-colored voxels survived the cutoff threshold
inside the FLAIR hyperintense tumor regions (1st row) and the AMT high uptake regions (2nd row). For the comparison, the detection of
the proliferating tumor cells inside the FLAIR hyperintense tumor regions was performed by thresholding of DWI-ADC image at two
cut-off values, 0.93 × 10−3 mm2/s (3rd row) and 1.22 × 10−3 mm2/s (4th row) which were reported as the ADC values for hypercelluarity
previously validated by histology [14, 21]
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uptake on PET. Low-grade gliomas have relatively low
proliferative activity and typically show low glucose me-
tabolism on PET. Still, the majority of low-grade gli-
omas show increased AMT uptake and trapping, which
can be attributed to increased tryptophan transport and
metabolism via the kynurenine pathway that can occur
in both low- and high-grade gliomas [8, 12]. Therefore,
tumoral AMT uptake measures are generally not very
accurate to predict glioma grade and proliferative activ-
ity. Our results are consistent with this and show that
IDSI could provide a better differentiation between
low-grade and high-grade gliomas by the estimation of
tumor cellularity.
Our preliminary data also demonstrate that IDSI is a
promising imaging modality for the non-invasive estima-
tion of glioma proliferative activity, as suggested by the
correlation between IDSI-derived cellularity and Ki-67
labeling index (Fig. 6). The correlation appeared to be
stronger in PET-derived tumor ROIs (Fig. 6b) than in
FLAIR-based ROIs, likely because the FLAIR-based
ROIs included non-tumorous edema in some cases
(Fig. 6a). In contrast, the PET-based ROIs included
tumor portions with high tryptophan metabolic activity
but excluded peritumoral vasogenic edema where pro-
liferative activity is low. However, PET-based ROIs can-
not be used in some low-grade gliomas showing low
AMT uptake, as was seen in one of our cases. Also,
malignant gliomas are often heterogenous and can con-
tain tumor portions showing different histologic grade
and proliferative activity, which may have similar high
AMT uptake on PET. Comparison of AMT-SUV and
IDSI cellularity maps (Fig. 5) suggests that IDSI may be
able to identify glioma subregions with the highest cel-
lularity, which may also be the most proliferative areas.
This could be tested in future studies by stereotactic,
image-guided sampling targeting tumor regions show-
ing different cellularity values.
Since AMT-PET and IDSI characterize different tumor
characteristics, the two imaging modalities may also pro-
vide complementary information in pre-treatment evalu-
ation of gliomas. IDSI may provide a parameter more
specific for tumor cellularity and less affected by other
factors such as tumoral ischemia or mass effects. On the
other hand, AMT is a unique PET tracer because its
Fig. 6 Close correlation of glioma Ki-67 labeling index with DWI-ADC (left) and IDSI-cellularity (right) obtained from the FLAIR ROI (a) and
AMT-SUV-based ROI (b). The correlation coefficients and p values are based on Pearson’s correlations
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tumoral accumulation is not only a reliable marker of
active glioma tissue but can also detect inflammatory
cell infiltration [31]; while necrotic regions of brain tu-
mors, as well as pure, glioma-induced vasogenic edema
show little to no AMT accumulation [5]. Thus, when
IDSI-MRI is applied in the region of high AMT uptake, it
becomes possible to evaluate cellularity due to tumor cell
proliferation and immune cell infiltration in active tumor
regions without including either necrosis or edema.
Other parameters derived from IDSI-MRI may also
be able to provide useful information by detecting such
necrotic and edematous regions, which likely show high
fluid ratio indicating the presence of increased extracel-
lular fluid due to the damaged membrane architecture.
In the current study, we focused on the assessment of
tumor cellularity, but future studies could evaluate
other IDSI-MRI-derived parameters (characterizing
fluid ratio, demyelination or axonal injury) to deter-
mine if they provide additional clinically useful infor-
mation in glioma evaluation.
There are several potential limitations in this study.
First, non-simultaneous acquisition of AMT PET and
MRI may lead to potential sources of errors in register-
ing locations of increased AMT and IDSI-defined cellu-
larity. This limitation could be overcome by the use of
integrated PET/MR systems able to simultaneously ac-
quire MR and PET images. Alternatively, tumor delin-
eation may be performed using FLAIR images; such a
region can include some peritumoral edema, but this
approach is more feasible clinically and does not re-
quire the use of PET images. Secondly, due to the small
number of diffusion encoding directions in clinical
MRI data, that may provide insufficient sensitivity for
cellularity, we calculated cellularity by summing the
fractional ratios of isotropic diffusion at the spectral
range of 0–1.0 × 10−3 mm2/s. The present study
adopted the cellularity threshold of spectral band (1.0 ×
10−3 mm2/s) from the previous postmortem study [14]
which reported the ADC value of 0.93 × 10−3 mm2/s as
a maximal ADC value of high grade gliomas. However,
as presented in Fig. 5, the thresholding of ADC map at
this threshold resulted in much less and sparser tu-
moral areas rather than at higher ADC threshold
(1.22 × 10−3 mm2/s), which was reported as an average
ADC values of high grade tumor in pediatric brain
[21]. The present study could not guarantee the effect
of higher spectral band threshold on the size of
tumoral area since pathological information is not
available at every tumoral area. This ambiguity of ac-
tual IDSI threshold may cause a significant variation
in cellularity across different histologic grades of gli-
omas. Thus, future studies should validate the results
of this study in larger cohorts with detailed pathology
including grade II, III, and IV gliomas.
Conclusions
By using IDSI to assess hypercellularity in newly-diagnosed
gliomas, we found that both FLAIR-defined and PET-
defined active tumor regions contain greater IDSI-derived
cellularity in high-grade gliomas compared to low-grade gli-
omas. Tumoral cellularity values showed a close correlation
with the glioma proliferative index as defined by histopath-
ology. These initial results hold the promise of a new, re-
fined imaging tool to better characterize glioma cellularity
and differentiate glioma grades using clinically applicable
MRI acquisitions.
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